Edition:
United States

Oramed Pharmaceuticals Inc (ORMP.OQ)

ORMP.OQ on NASDAQ Stock Exchange Capital Market

8.61USD
1:04pm EDT
Change (% chg)

$0.28 (+3.36%)
Prev Close
$8.33
Open
$8.72
Day's High
$8.72
Day's Low
$8.59
Volume
28,891
Avg. Vol
7,863
52-wk High
$9.09
52-wk Low
$5.70

ORMP.OQ

Chart for ORMP.OQ

About

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $111.41
Shares Outstanding(Mil.): 13.29
Dividend: --
Yield (%): --

Financials

  ORMP.OQ Industry Sector
P/E (TTM): -- 139.31 17.29
EPS (TTM): -0.95 -- --
ROI: -34.10 2.29 -5.84
ROE: -46.55 0.06 -5.23

BRIEF-Oramed receives Israel regulatory approval

* Oramed receives Israel regulatory approval to conduct human study for new oral leptin capsule

May 02 2017

BRIEF-Oramed Pharmaceuticals Inc files for mixed shelf of up to $100 mln

* Oramed pharmaceuticals inc - files for a mixed shelf of up to $100 million - sec filing Source text (http://bit.ly/2j8k1FJ) Further company coverage:

Jan 11 2017

BRIEF-Oramed's ORMD-0901 safe and well tolerated in phase IB study

* Oramed's ORMD-0901 (oral GLP-1 analog) found safe and well tolerated in phase IB study

Nov 29 2016

More From Around the Web

Earnings vs. Estimates